Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.

  • Braf−/− ER(TM)-HRAS(G12V) MEFs were transduced with retroviral constructs encoding the indicated BRAF proteins and treated with 4-HT to release oncogenic RAS, or ethanol as a control. Following incubation with 1 μM vemurafenib, 1 μM dabrafenib or DMSO as a control for 4 h, cells were subjected to western blot analysis with the indicated antibodies.

    Leukemia, 2016, 30(4):937-46. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blots for untreated, early, and late tumors.

    Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.

  • Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

    The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [3]
(Cell-free assay)
B-Raf [3]
(Cell-free assay)
C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MW\LbY5ie2ViQYPzZZk> MlnmTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch|ryP NG\VXWIzPDlyME[3Ny=>
SK-MEL-28 NYTKeYsyU2mwYYPlJGF{e2G7 M1\aOlEhcA>? MlvvTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJGVTUyCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFA1KM7:TR?= NXfpSlNYOjR7MEC2O|M>
HepG2 MnTwT4lv[XOnIFHzd4F6 NFzlNlJKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1? Ml\5NlQ6ODB4N{O=
COLO205 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfi[45FUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPNlA2KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xODdizszN NUTGWYlVOjR7MEC2O|M>
HepG2 NYDxfnlLTnWwY4Tpc44hSXO|YYm= NFXUeXM1PSCvaX6= MWTEUXNQ MUPJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG|dYLl[EBi\nSncjC2NEBucW6|IHL5JI9lgXO|ZYmgZoxwfCC|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch|ryP MVyyOFkxODZ5Mx?=
HFF M{m4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f1XFExKM7:TR?= MW[3NkBp NHXIb25FVVOR Mkj2TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKGi3bXHuJGhHTiClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEJvUnHmJJdqfGhiSVO1NEBw\iB|IN88US=> NF21[GYzOzh2NECzPC=>
SK-MEL-28 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\afFExKM7:TR?= MnvBO|IhcA>? MonSSG1UVw>? MYrJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN NIXpcJQzOzh2NECzPC=>
A375P-F11 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjifYdLOTBizszN NV\QR3B1PzJiaB?= M3LGO2ROW09? M33GbmlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0> NH;XbHMzOzh2NECzPC=>
MALME-3M MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TxdFExKM7:TR?= NYTZRmRrPzJiaB?= MXfEUXNQ NEnLVHJKSzVyPUGgcm0> MWqyN|g1PDB|OB?=
UACC-62 NV3Fb5Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvWXnZiOTBizszN MlzoO|IhcA>? MnjiSG1UVw>? MX7JR|UxRTFibl2= Ml7KNlM5PDRyM{i=
C32TG M{fGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHEc|l3OTBizszN NXHBV2llPzJiaB?= MnjRSG1UVw>? MWrJR|UxRTFibl2= NYjWUHdVOjN6NESwN|g>
SK-MEL-1 M{jrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{juSlExKM7:TR?= MnfGO|IhcA>? NI\YdIJFVVOR NUj6VmtrUUN3ME2yJI5O MV2yN|g1PDB|OB?=
M14 NYj4XXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37GNFExKM7:TR?= MYi3NkBp Mn\DSG1UVw>? MVHJR|UxRTJibl2= NYLlNW92OjN6NESwN|g>
SK-MEL-28 M4PWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjSU3hlOTBizszN MnrOO|IhcA>? MmHqSG1UVw>? M2[3[GlEPTB;MzDuUS=> NYe2UWI4OjN6NESwN|g>
A375 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC5NVAh|ryP NFe1b4Y4OiCq MYPEUXNQ M1jvOWlEPTB;NDDuUS=> M4\rTVI{QDR2MEO4
DU-4475 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyxNEDPxE1? M4n1blczKGh? M2rGbmROW09? MWDJR|UxRTVibl2= NW\3UJd5OjN6NESwN|g>
UACC-257 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLKVXFuOTBizszN MUi3NkBp MX7EUXNQ NWPrPI9OUUN3ME22JI5O MXSyN|g1PDB|OB?=
Colo 205 M1Tyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jITVExKM7:TR?= NYD4WGVUPzJiaB?= NG\oNJpFVVOR MlrpTWM2OD15IH7N NGr5NWozOzh2NECzPC=>
SK-MEL-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjvNVAh|ryP NGXsNm44OiCq MljESG1UVw>? M3yxfmlEPTB;NzDuUS=> MYCyN|g1PDB|OB?=
SH-4 NETj[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS3VFFlOTBizszN NFG0NY44OiCq MlXPSG1UVw>? NEnVWlJKSzVyPUigcm0> M3PFWVI{QDR2MEO4
A101D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HmTVExKM7:TR?= MnnWO|IhcA>? M2rhfmROW09? M{LRbmlEPTB;OTDuUS=> NE\kZWwzOzh2NECzPC=>
ES-2 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIdnVlOTBizszN M1j6XFczKGh? NHnTTHNFVVOR NVrLOVFkUUN3ME21N{BvVQ>? MmnLNlM5PDRyM{i=
HT-29 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jTOlExKM7:TR?= MVy3NkBp MnjUSG1UVw>? MmL3TWM2OD14NjDuUS=> Mmf6NlM5PDRyM{i=
SW1417 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGxNEDPxE1? NEj4SVc4OiCq NWf3Smw1TE2VTx?= MVTJR|UxRTF3ODDuUS=> NIO3RmgzOzh2NECzPC=>
SW872 M1jER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPNWHJxOTBizszN Mk\pO|IhcA>? M1vIOmROW09? MYfJR|UxRTN5NzDuUS=> MUWyN|g1PDB|OB?=
RKO NXH5NVl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjZNVAh|ryP MnrkO|IhcA>? MlnUSG1UVw>? MUjJR|UxRTJwNUKyJO69VQ>? MVuyN|g1PDB|OB?=
A673 NGrHepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXwNVAh|ryP NFfJWYQ4OiCq M1vt[2ROW09? MY\JR|UxRTFyIN88US=> NIGxS3czOzh2NECzPC=>
GCT Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNEDPxE1? MVu3NkBp NGH1UoFFVVOR NYT2OW9xUUN3ME2xNEDPxE1? MUCyN|g1PDB|OB?=
WM-115 M{i5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SwWFExKM7:TR?= NIWyWXY4OiCq NV\TbHFGTE2VTx?= MkfMTWM2OD13IH7N MV2yN|g1PDB|OB?=
YUMAC NUC2SodJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITOeFcyOCEQvF2= MkfMO|IhcA>? MlL5SG1UVw>? NFu0[G5KSzVyPUWgcm0> NGW3eFYzOzh2NECzPC=>
OV-90 NYDWdHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNEDPxE1? MWC3NkBp NH71TVVFVVOR NUKzOVhKUUN3ME2yPUBvVQ>? NVvJVpJwOjN6NESwN|g>
NCI-H508 NI[ydHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17kSlExKM7:TR?= MWW3NkBp NH7YfllFVVOR NV7XNJF1UUN3ME2xNEDPxE1? MnjhNlM5PDRyM{i=
MDA-MB-231 M2rVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGxNEDPxE1? M2\DZlczKGh? MWTEUXNQ NHv3RnFKSzVyPUGwJO69VQ>? MknPNlM5PDRyM{i=
SW756 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrZc3oyOCEQvF2= MoHkO|IhcA>? NH;BeFZFVVOR MX7JR|UxRTFyIN88US=> NVz4TYhPOjN6NESwN|g>
SW-837 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWyNVAh|ryP M1\lT|czKGh? M1Plc2ROW09? MmnPTWM2OD1zMDFOwG0> MlLkNlM5PDRyM{i=
UMUC-3 M4PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxNEDPxE1? NGHM[2g4OiCq M3HJXWROW09? MkjvTWM2OD1zMDFOwG0> MmrKNlM5PDRyM{i=
LS-174T NVrUfZJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LqN|ExKM7:TR?= NXTqdVJLPzJiaB?= NYK2OGdmTE2VTx?= NYLWV4ZUUUN3ME2xNEDPxE1? NWHHc2t1OjN6NESwN|g>
A549 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxNEDPxE1? MXm3NkBp NGf1NZZFVVOR M{XOdmlEPTB;MUCg{txO MmrENlM5PDRyM{i=
SHP-77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\Zb|FGOTBizszN NYPDV|hvPzJiaB?= MUPEUXNQ MXLJR|UxRTFyIN88US=> MnuwNlM5PDRyM{i=
SW480 NGmxZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mTogyOCEQvF2= NVfjbYRVPzJiaB?= MkHMSG1UVw>? M4DJZ2lEPTB;MUCg{txO NVnseJk5OjN6NESwN|g>
DLD-1 M33rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOxNEDPxE1? M{jzblczKGh? NHu1Z2xFVVOR MVfJR|UxRTFyIN88US=> M4LQ[FI{QDR2MEO4
HCT-116 NITDOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13Vd|ExKM7:TR?= MV:3NkBp MmnXSG1UVw>? M4PVSGlEPTB;MUCg{txO M{jaT|I{QDR2MEO4
NCI-H747 M1m0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzpNVAh|ryP MUG3NkBp MY\EUXNQ M17NOGlEPTB;MUCg{txO NYTUcZlnOjN6NESwN|g>
T-84 NHq0OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6[|ExKM7:TR?= M4HZRVczKGh? MX\EUXNQ NUPhTJBvUUN3ME2xNEDPxE1? MXOyN|g1PDB|OB?=
NCI-H460 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe4THFIOTBizszN MlXpO|IhcA>? MWHEUXNQ NIDLTXpKSzVyPUGwJO69VQ>? MVeyN|g1PDB|OB?=
Calu-6 M{j2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L6T|ExKM7:TR?= NVXoRpczPzJiaB?= MlmzSG1UVw>? NH\uXI1KSzVyPUGwJO69VQ>? NGH4T5MzOzh2NECzPC=>
HCC-2998 NX3aN2IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xNEDPxE1? NWHwVXhxPzJiaB?= NFzQRmJFVVOR M2ThSmlEPTB;MUCg{txO M4XuPVI{QDR2MEO4
LS1034 MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqzXpgyOCEQvF2= MUO3NkBp NHLsN3dFVVOR MnzSTWM2OD1zMDFOwG0> NHTEZ3IzOzh2NECzPC=>
CHP-212 Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjZNVAh|ryP MYK3NkBp M1;3NGROW09? NUL5V2VtUUN3ME2xNEDPxE1? MUiyN|g1PDB|OB?=
SK-N-AS MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNEDPxE1? MkfqO|IhcA>? M4XzVWROW09? MWHJR|UxRTFyIN88US=> M3zsO|I{QDR2MEO4
BFTC-905 NGD1So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqxRpF2OTBizszN Mon2O|IhcA>? Mlv1SG1UVw>? MnLVTWM2OD1zMDFOwG0> MkXaNlM5PDRyM{i=
HuT78 NIK0[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[4OY4yOCEQvF2= Ml3pO|IhcA>? NI\tOJpFVVOR MXzJR|UxRTV{IH7N M3j4TVI{QDR2MEO4
RPMI-8226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LPO|ExKM7:TR?= NVS1WYVEPzJiaB?= MnnRSG1UVw>? MYHJR|UxRTJ4MzDuUS=> NF70WpkzOzh2NECzPC=>
BC-3 MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjyNVAh|ryP NXvlb4w1PzJiaB?= MnjySG1UVw>? MVPJR|UxRTJ5NzDuUS=> NYXr[4UyOjN6NESwN|g>
ACHN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? NWe3TlFyPzJiaB?= NVjZ[m5FTE2VTx?= MnvyTWM2OD1{OUSgcm0> MlTXNlM5PDRyM{i=
JRT3-T35 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxNEDPxE1? MXW3NkBp NHfoeXRFVVOR MlHsTWM2OD1{OUWgcm0> NFOyR4QzOzh2NECzPC=>
SK-MES-1 NXnh[Xh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHKdJAyOCEQvF2= M3PYcFczKGh? MUnEUXNQ NW[4d2NkUUN3ME2zNlkhdk1? MlHxNlM5PDRyM{i=
CESS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNEDPxE1? M3;SOFczKGh? NV:4OFdCTE2VTx?= NWLEd41YUUN3ME20PVchdk1? NYn1VlB[OjN6NESwN|g>
H4 M{S1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fkPVExKM7:TR?= Mn\kO|IhcA>? NIL2OpJFVVOR NXn1VlV5UUN3ME22NVkhdk1? MYSyN|g1PDB|OB?=
BC-1 NHjpcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXwT3UyOCEQvF2= Mo\aO|IhcA>? MmHSSG1UVw>? NVjD[oZwUUN3ME23NFQhdk1? Mkn6NlM5PDRyM{i=
DB NYTDdIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\FNVAh|ryP MlXnO|IhcA>? NEXyU3FFVVOR M2\oXGlEPTB;OEezJI5O NVfaUpBsOjN6NESwN|g>
RPMI-6666 NFyxdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm2N|NLOTBizszN NWK5V252PzJiaB?= NFjqTmxFVVOR NY\YUIZTUUN3ME25Nlghdk1? MoO4NlM5PDRyM{i=
MC/CAR Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKzenZWOTBizszN MXm3NkBp MoTaSG1UVw>? MUnJR|UxRTFwMECyJO69VQ>? M1PibFI{QDR2MEO4
SNU-1 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXu[nR[OTBizszN M4\oWVczKGh? Ml3XSG1UVw>? NETMN5RKSzVyPUGuOVAyKM7:TR?= NGG0XIkzOzh2NECzPC=>
CEM/C1 M{OxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjCenAyOCEQvF2= Mm\6O|IhcA>? MWfEUXNQ MULJR|UxRTFwN{ezJO69VQ>? NEjVNoUzOzh2NECzPC=>
GDM-1 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[xNEDPxE1? M{TLSVczKGh? NG\0[ZZFVVOR NHfCe|ZKSzVyPUGuPVk4KM7:TR?= MVuyN|g1PDB|OB?=
HT-1080 NYfjeXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInYRWoyOCEQvF2= MoG1O|IhcA>? M1;CRmROW09? NYrER3ltUUN3ME2yMlAxPCEQvF2= MViyN|g1PDB|OB?=
HL-60 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3MZ2QyOCEQvF2= NX7wRlJjPzJiaB?= MmLCSG1UVw>? MVzJR|UxRTJwMUe4JO69VQ>? NELJPVEzOzh2NECzPC=>
C3A MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? NXn1eGt2PzJiaB?= M4izT2ROW09? NWj0Noo3UUN3ME21MlQyPCEQvF2= NHL5SXEzOzh2NECzPC=>
MES-SA NGW1[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLkPHoyOCEQvF2= MXK3NkBp NX3aSVJ3TE2VTx?= MkLuTWM2OD14Lkm4PUDPxE1? NGXB[|QzOzh2NECzPC=>
22Rv1 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNEDPxE1? NFK2TlQ4OiCq M1XNcGROW09? MnW0TWM2OD1zMDFOwG0> MnrzNlM5PDRyM{i=
647-V NXznWW4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DVVVExKM7:TR?= M4f0R|czKGh? NHS2TlhFVVOR NGLCblRKSzVyPUGwJO69VQ>? NGniVlgzOzh2NECzPC=>
786-O NXLMWFI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjYTZFyOTBizszN NYLUb3B2PzJiaB?= M1v2c2ROW09? NUC1S|R1UUN3ME2xNEDPxE1? M3:3fVI{QDR2MEO4
A172 NYS4bY02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxNEDPxE1? Mn22O|IhcA>? NHrC[ItFVVOR M2XwZWlEPTB;MUCg{txO MlTxNlM5PDRyM{i=
A204 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK0OGsyOCEQvF2= NH;se4c4OiCq MoXDSG1UVw>? M{Xt[WlEPTB;MUCg{txO Mn7pNlM5PDRyM{i=
A427 NXHPT5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXKV5NEOTBizszN M3mxRVczKGh? NXXubVd1TE2VTx?= NXfrZVJTUUN3ME2xNEDPxE1? MoDXNlM5PDRyM{i=
A431 NGHxSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[1N3lNOTBizszN MYC3NkBp M2[xOmROW09? Ml;aTWM2OD1zMDFOwG0> MYmyN|g1PDB|OB?=
A2780 NX;2RpNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLuNVAh|ryP M2XNUFczKGh? Mn7sSG1UVw>? NETZcZdKSzVyPUGwJO69VQ>? MWCyN|g1PDB|OB?=
ARH-77 NXLKU3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfYO4ljOTBizszN MYC3NkBp M1[1bmROW09? NI[5WZZKSzVyPUGwJO69VQ>? MVuyN|g1PDB|OB?=
Be(2)C MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fFNFExKM7:TR?= MnLlO|IhcA>? M4PyRWROW09? MWrJR|UxRTFyIN88US=> M4Lob|I{QDR2MEO4
BT-20 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[xNEDPxE1? MkPXO|IhcA>? NEnoVYxFVVOR NEHSbldKSzVyPUGwJO69VQ>? NHr1WpozOzh2NECzPC=>
BxPc3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[xNEDPxE1? M{jhZVczKGh? M3vnNGROW09? NUG1V3ZnUUN3ME2xNEDPxE1? M3zudVI{QDR2MEO4
C-4 I NEnSXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrhRnFKOTBizszN NYXBWHJWPzJiaB?= MYTEUXNQ NV;0cItUUUN3ME2xNEDPxE1? MVGyN|g1PDB|OB?=
C33A M4D5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL3T5EyOCEQvF2= M3LhelczKGh? M1vqW2ROW09? Ml31TWM2OD1zMDFOwG0> M4ewfVI{QDR2MEO4
CAL-27 NI\I[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNEDPxE1? NXTC[|hUPzJiaB?= NIT0cYFFVVOR MYLJR|UxRTFyIN88US=> NWLEfJFQOjN6NESwN|g>
CAL-62 NIC0VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPyWVFvOTBizszN MWq3NkBp MlnSSG1UVw>? MV3JR|UxRTFyIN88US=> Mm[wNlM5PDRyM{i=
Calu-3 NUP0b|VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDXTXdJOTBizszN Mof3O|IhcA>? MU\EUXNQ MoDmTWM2OD1zMDFOwG0> NWjjXGV3OjN6NESwN|g>
CaOV3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;lVFExKM7:TR?= Mkm4O|IhcA>? M3K4emROW09? Moq4TWM2OD1zMDFOwG0> NYHKWJJbOjN6NESwN|g>
CGTHW1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDFNVAh|ryP NH\QWnA4OiCq NVrIUXJJTE2VTx?= NVPw[GR3UUN3ME2xNEDPxE1? M4DDVVI{QDR2MEO4
CHL-1 NGnCbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhNVAh|ryP MWq3NkBp M{fDRmROW09? MnPTTWM2OD1zMDFOwG0> MVKyN|g1PDB|OB?=
Colo320DM MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn4UlEyOCEQvF2= M3;LXFczKGh? NVzWVGt2TE2VTx?= NGfOZoVKSzVyPUGwJO69VQ>? MYCyN|g1PDB|OB?=
Colo704 M4XSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnizNVAh|ryP MUC3NkBp MnXKSG1UVw>? NUnpc3Z1UUN3ME2xNEDPxE1? MVGyN|g1PDB|OB?=
COR-L23 M1\FWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXBNVAh|ryP M3;0PFczKGh? MoTzSG1UVw>? Ml3wTWM2OD1zMDFOwG0> MWeyN|g1PDB|OB?=
CRO-AP2 M4\vVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fENFExKM7:TR?= MkjWO|IhcA>? NIXNZnhFVVOR MXvJR|UxRTFyIN88US=> NGewXG8zOzh2NECzPC=>
Daudi M2PZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[xNEDPxE1? M376TlczKGh? NY\WWIx3TE2VTx?= MUfJR|UxRTFyIN88US=> M3LtPFI{QDR2MEO4
DOTC 24510 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjXdI4yOCEQvF2= NVmzd3hmPzJiaB?= MoLFSG1UVw>? MX3JR|UxRTFyIN88US=> NWq3THc5OjN6NESwN|g>
DU-145 NXvs[|NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS0WVQ1OTBizszN NH:1ZVI4OiCq MkHrSG1UVw>? M1zGN2lEPTB;MUCg{txO M1mzWFI{QDR2MEO4
EB-3 NXvySHkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjlNVAh|ryP MW[3NkBp Mlv6SG1UVw>? NEjNRVVKSzVyPUGwJO69VQ>? MWWyN|g1PDB|OB?=
EFM-19 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNEDPxE1? M1:zOFczKGh? M{XLe2ROW09? M3[zTGlEPTB;MUCg{txO MUiyN|g1PDB|OB?=
EKVX NVTORVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXLNW0yOCEQvF2= Mn7GO|IhcA>? MYXEUXNQ MYfJR|UxRTFyIN88US=> NXHnV3lMOjN6NESwN|g>
FaDu NIHzZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxNEDPxE1? M1XjbFczKGh? NWqzdY86TE2VTx?= NVnz[45mUUN3ME2xNEDPxE1? NIC1N|AzOzh2NECzPC=>
G401 M1[xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXQ[3UyOCEQvF2= MVq3NkBp Ml31SG1UVw>? MXXJR|UxRTFyIN88US=> NHj6UnIzOzh2NECzPC=>
HCC-70 MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LpXVExKM7:TR?= NWDqVXUzPzJiaB?= NXPjN2ptTE2VTx?= M1TPeWlEPTB;MUCg{txO NVTtOYpsOjN6NESwN|g>
HCC-1954 NF;xO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? MX63NkBp NFTzNotFVVOR MXrJR|UxRTFyIN88US=> NHqyco8zOzh2NECzPC=>
Hela MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljQNVAh|ryP NXLPZYc5PzJiaB?= M33GTGROW09? NH[x[WxKSzVyPUGwJO69VQ>? M32yelI{QDR2MEO4
Hep3B Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3l[VFHOTBizszN NWG5flZsPzJiaB?= NET6OJJFVVOR MUXJR|UxRTFyIN88US=> MUiyN|g1PDB|OB?=
HMCB M{nWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHRNVAh|ryP M37qZVczKGh? NGjzPFVFVVOR NWHEd4E5UUN3ME2xNEDPxE1? NVj4dpVQOjN6NESwN|g>
HN5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi1XWYyOCEQvF2= MlnZO|IhcA>? MkPMSG1UVw>? MWPJR|UxRTFyIN88US=> M3S0ZVI{QDR2MEO4
HOS NX7WNFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX73T5lrOTBizszN NXvkflR3PzJiaB?= MXzEUXNQ NYjz[m9IUUN3ME2xNEDPxE1? NUf0S4lCOjN6NESwN|g>
HPAF-II NUHk[oRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr1NVAh|ryP MVm3NkBp MkS5SG1UVw>? NWDsfIpQUUN3ME2xNEDPxE1? NVu3ToNFOjN6NESwN|g>
Hs746.T MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX75XGhnOTBizszN NGK4[VE4OiCq MWfEUXNQ MVXJR|UxRTFyIN88US=> M4ixT|I{QDR2MEO4
HT NEnzSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexNEDPxE1? MVW3NkBp MWjEUXNQ MmfjTWM2OD1zMDFOwG0> MW[yN|g1PDB|OB?=
HT-3 M4H4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILRUlcyOCEQvF2= MX23NkBp MYjEUXNQ NFfOWo9KSzVyPUGwJO69VQ>? MWWyN|g1PDB|OB?=
HuNS-1 M{PLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT5NVAh|ryP NW\We4dUPzJiaB?= NXXMepFPTE2VTx?= M1jaPWlEPTB;MUCg{txO MWqyN|g1PDB|OB?=
IGROV1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jkbVExKM7:TR?= NXvxUZQ3PzJiaB?= NIHuSXBFVVOR NInsU3pKSzVyPUGwJO69VQ>? MoXLNlM5PDRyM{i=
J82 NGHvVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr4NJhTOTBizszN NYLENlFKPzJiaB?= M{DpPGROW09? MUjJR|UxRTFyIN88US=> M3PSUFI{QDR2MEO4
JM1 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDiTZQyOCEQvF2= MmDUO|IhcA>? M1XkTmROW09? NFvOUHVKSzVyPUGwJO69VQ>? NWPkN|R{OjN6NESwN|g>
Kato III M136e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjsfYkyOCEQvF2= Mo[5O|IhcA>? NF;mRXZFVVOR MXnJR|UxRTFyIN88US=> MV6yN|g1PDB|OB?=
KHOS-240S M{DoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTHfmsyOCEQvF2= MnWwO|IhcA>? MkLGSG1UVw>? NUXjN4lPUUN3ME2xNEDPxE1? MnHKNlM5PDRyM{i=
KM-12 NInzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnNNVAh|ryP NWPMPXVoPzJiaB?= NX3UPWlzTE2VTx?= MmfqTWM2OD1zMDFOwG0> M1nhUlI{QDR2MEO4
KPL-1 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\6NVAh|ryP NHLEZYI4OiCq MVnEUXNQ MXTJR|UxRTFyIN88US=> MoK3NlM5PDRyM{i=
KYSE-30 M4foWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF20[3UyOCEQvF2= NUX4PGNVPzJiaB?= NFLpeZhFVVOR MVjJR|UxRTFyIN88US=> MmW2NlM5PDRyM{i=
LNCaP MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTVS5oyOCEQvF2= M1PqclczKGh? NXnqO2U1TE2VTx?= NGTTO3ZKSzVyPUGwJO69VQ>? M1ToVlI{QDR2MEO4
MCF-7 M1vrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojFNVAh|ryP NFHVcYo4OiCq MmK1SG1UVw>? Mlu0TWM2OD1zMDFOwG0> M2HIZlI{QDR2MEO4
MC-IXC NYLyVVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVixNEDPxE1? NHSwc5c4OiCq NFHXdmtFVVOR M1fCWmlEPTB;MUCg{txO MXKyN|g1PDB|OB?=
MDA-MB-175 VII NWXHPIZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDoVIUyOCEQvF2= NYfHPJpCPzJiaB?= NX2yNYI1TE2VTx?= NHPlOIVKSzVyPUGwJO69VQ>? MoHJNlM5PDRyM{i=
MDA-MB-468 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r5b|ExKM7:TR?= NEDqeY04OiCq NYTk[IJoTE2VTx?= MYTJR|UxRTFyIN88US=> NVjqTWZqOjN6NESwN|g>
MiaPaCa MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fMOVExKM7:TR?= MXe3NkBp NYjpUHNPTE2VTx?= NXvUZZdbUUN3ME2xNEDPxE1? M{[0c|I{QDR2MEO4
Molt-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? MnTNO|IhcA>? M4PZN2ROW09? MnT0TWM2OD1zMDFOwG0> NIrIZ3ozOzh2NECzPC=>
NCI-ADR/RES NX74bmExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3NVAh|ryP Ml;YO|IhcA>? M2PaPWROW09? MUXJR|UxRTFyIN88US=> NUfsenNrOjN6NESwN|g>
NCI-H69 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHKeoVYOTBizszN MXi3NkBp Mn\XSG1UVw>? NX7kUnJHUUN3ME2xNEDPxE1? MnLDNlM5PDRyM{i=
NCI-H82 NVnJboNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXiyV5hzOTBizszN M2\YWlczKGh? MX\EUXNQ NGnWbnFKSzVyPUGwJO69VQ>? NEX1VG4zOzh2NECzPC=>
NCI-N87 M2nLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M132Z|ExKM7:TR?= MVW3NkBp MV;EUXNQ M3vTRWlEPTB;MUCg{txO M3rsVFI{QDR2MEO4
NCI-H146 NGm5RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxNEDPxE1? NUfBNFlSPzJiaB?= MXzEUXNQ MkS2TWM2OD1zMDFOwG0> Mm\qNlM5PDRyM{i=
NCI-H157 M4TldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3zNVAh|ryP M3nZN|czKGh? NHHCN5pFVVOR NYryfmhpUUN3ME2xNEDPxE1? M1ruRVI{QDR2MEO4
NCI-H187 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNEDPxE1? M1PJOFczKGh? NH:yRm5FVVOR MULJR|UxRTFyIN88US=> MlPoNlM5PDRyM{i=
NCI-H209 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPWNVAh|ryP MkDwO|IhcA>? NYXCeVliTE2VTx?= M1jKfGlEPTB;MUCg{txO MV[yN|g1PDB|OB?=
NCI-H226 NGLNZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6SVExKM7:TR?= MYS3NkBp MUTEUXNQ MlLvTWM2OD1zMDFOwG0> M17TSlI{QDR2MEO4
NCI-H292 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fRZlExKM7:TR?= NUjWVVg1PzJiaB?= NHPWVplFVVOR MoHqTWM2OD1zMDFOwG0> NUS4RXRJOjN6NESwN|g>
NCI-H322 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxNEDPxE1? MXy3NkBp NIKyVYZFVVOR MVzJR|UxRTFyIN88US=> MlG5NlM5PDRyM{i=
NCI-H358 NU\VVG9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xNEDPxE1? MWe3NkBp NWDuTFhITE2VTx?= MnjvTWM2OD1zMDFOwG0> NF7RV2ozOzh2NECzPC=>
NCI-H520 M{e0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jPfFExKM7:TR?= NWPofY9LPzJiaB?= MXfEUXNQ NF\mN2dKSzVyPUGwJO69VQ>? M2rBdlI{QDR2MEO4
NCI-H526 NVS0OYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\EPVExKM7:TR?= NVPCVnNTPzJiaB?= MkDsSG1UVw>? MUfJR|UxRTFyIN88US=> NEfzR3IzOzh2NECzPC=>
NCI-H630 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEizZY4yOCEQvF2= NXHXU4FCPzJiaB?= MonsSG1UVw>? MmLzTWM2OD1zMDFOwG0> MVqyN|g1PDB|OB?=
NCI-H661 NVjjVWo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vjS|ExKM7:TR?= NYfZTGtvPzJiaB?= MY\EUXNQ M133W2lEPTB;MUCg{txO M3T5V|I{QDR2MEO4
NCI-H716 MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXLRVI6OTBizszN NHrWTVU4OiCq NInWb5VFVVOR NXXLeIllUUN3ME2xNEDPxE1? MmTTNlM5PDRyM{i=
NCI-H1563 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP2O2FDOTBizszN MnezO|IhcA>? Ml7CSG1UVw>? MXHJR|UxRTFyIN88US=> MnfVNlM5PDRyM{i=
NCI-H1792 NGf0cW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T2eVExKM7:TR?= NIDtbIE4OiCq NYCxWnFGTE2VTx?= M3;jZWlEPTB;MUCg{txO M13OeFI{QDR2MEO4
NCI-H2030 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknuNVAh|ryP MWm3NkBp NFfOdmtFVVOR M2nC[GlEPTB;MUCg{txO MV2yN|g1PDB|OB?=
NCI-H2052 NF7XbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5NVAh|ryP NG\rOVM4OiCq NUiwfmRVTE2VTx?= NYTsXop3UUN3ME2xNEDPxE1? MnnDNlM5PDRyM{i=
NCI-H2122 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjwNVAh|ryP MmXtO|IhcA>? NYH3O|M4TE2VTx?= NV\ORnBUUUN3ME2xNEDPxE1? NHzn[2QzOzh2NECzPC=>
NCI-H2228 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW4d2hPOTBizszN MlflO|IhcA>? M3XpOmROW09? NVfPSoJZUUN3ME2xNEDPxE1? NYKzUVJJOjN6NESwN|g>
OE-19 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCxNEDPxE1? MlnMO|IhcA>? M4Hyc2ROW09? NGriOo9KSzVyPUGwJO69VQ>? MoLtNlM5PDRyM{i=
OE-21 NYG4b5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK1NVAh|ryP M{S2flczKGh? NGnmW2RFVVOR NHKxZ5dKSzVyPUGwJO69VQ>? M4\EfFI{QDR2MEO4
OE-33 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rnNlExKM7:TR?= MVq3NkBp NGnvT5BFVVOR NW\C[ldtUUN3ME2xNEDPxE1? NGDwSVQzOzh2NECzPC=>
OVCAR-3 NFvFNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW5NVAh|ryP M2fiSVczKGh? NXnXdJN5TE2VTx?= M3fORmlEPTB;MUCg{txO NUC3SI1NOjN6NESwN|g>
OVCAR-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNEDPxE1? NYK4WplSPzJiaB?= MlzaSG1UVw>? MXHJR|UxRTFyIN88US=> MkLlNlM5PDRyM{i=
OVCAR-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rhU|ExKM7:TR?= MXm3NkBp NG\idHhFVVOR Mnj1TWM2OD1zMDFOwG0> MUWyN|g1PDB|OB?=
P3HR-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLtT5kyOCEQvF2= NVPST28xPzJiaB?= M1TJTGROW09? MkTvTWM2OD1zMDFOwG0> M1jrZ|I{QDR2MEO4
PC-3 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSxNEDPxE1? MUK3NkBp M3[2N2ROW09? NXzQNG5FUUN3ME2xNEDPxE1? NHjUUlQzOzh2NECzPC=>
Raji MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PPTFExKM7:TR?= NWXr[oZ4PzJiaB?= NXXJUFA4TE2VTx?= NXjCZnhUUUN3ME2xNEDPxE1? MUeyN|g1PDB|OB?=
RD MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfSXIkyOCEQvF2= M1z3blczKGh? NF\nNW5FVVOR NU[1XmtrUUN3ME2xNEDPxE1? MX2yN|g1PDB|OB?=
RD-ES Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHKNVAh|ryP NGH5eXk4OiCq MVnEUXNQ Mn\VTWM2OD1zMDFOwG0> Ml64NlM5PDRyM{i=
RL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxNEDPxE1? NXzse45IPzJiaB?= M3nBU2ROW09? MoDUTWM2OD1zMDFOwG0> NV;DS4J[OjN6NESwN|g>
SaOS2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO5NVAh|ryP NEW2S3Y4OiCq NF7HfHRFVVOR MlrQTWM2OD1zMDFOwG0> MXyyN|g1PDB|OB?=
SCC-9 NHLmZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNEDPxE1? Mkj6O|IhcA>? MYrEUXNQ NGHobIVKSzVyPUGwJO69VQ>? MX6yN|g1PDB|OB?=
SCC-12 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxNEDPxE1? NYTJcHQ{PzJiaB?= M3TlU2ROW09? NVPCfllUUUN3ME2xNEDPxE1? NV;sZ5dzOjN6NESwN|g>
SCC-13 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf4PHAyOCEQvF2= NYPxUXE1PzJiaB?= MUHEUXNQ NUPVdJFYUUN3ME2xNEDPxE1? MWqyN|g1PDB|OB?=
SCC-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGxNEDPxE1? NHnFOlQ4OiCq MnTRSG1UVw>? M1ruV2lEPTB;MUCg{txO NFrRWWkzOzh2NECzPC=>
SCC-25 M3XKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[yc3N7OTBizszN M2m5NVczKGh? MX3EUXNQ MlzYTWM2OD1zMDFOwG0> NHXEd5gzOzh2NECzPC=>
SCLC-3 NVzUc25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofvNVAh|ryP MWK3NkBp Mn7BSG1UVw>? NWHFV5hlUUN3ME2xNEDPxE1? MWGyN|g1PDB|OB?=
SF-268 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\UNVAh|ryP MmLiO|IhcA>? MVHEUXNQ NULMNGZwUUN3ME2xNEDPxE1? MWmyN|g1PDB|OB?=
SF-295 NVLKRoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HXV|ExKM7:TR?= M1jYVFczKGh? NFP0d4pFVVOR NWWwZYxQUUN3ME2xNEDPxE1? MlTjNlM5PDRyM{i=
SJRH30 NFHzW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXIXpNvOTBizszN MYe3NkBp MUnEUXNQ MYnJR|UxRTFyIN88US=> NEGzRogzOzh2NECzPC=>
SK-BR-3 NYTnUI03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzSTpUyOCEQvF2= MYO3NkBp MkLkSG1UVw>? MXvJR|UxRTFyIN88US=> NFfXUYczOzh2NECzPC=>
SK-LMS-1 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKxNEDPxE1? MWW3NkBp NF3JS3JFVVOR NHG1PZVKSzVyPUGwJO69VQ>? MVyyN|g1PDB|OB?=
SK-N-DZ NILROW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHKNVAh|ryP MVe3NkBp NH23WmpFVVOR NEXWNY9KSzVyPUGwJO69VQ>? MnSzNlM5PDRyM{i=
SK-N-F1 NELXTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnHNVAh|ryP MY[3NkBp NIjOTIdFVVOR MYTJR|UxRTFyIN88US=> MV[yN|g1PDB|OB?=
SKOV-3 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;MTFExKM7:TR?= M3HIblczKGh? MkS4SG1UVw>? NXrPclhOUUN3ME2xNEDPxE1? MWOyN|g1PDB|OB?=
SK-UT-1 M37NPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu3UJJDOTBizszN MVi3NkBp M1LwUWROW09? NYDsTo5oUUN3ME2xNEDPxE1? NInVRY8zOzh2NECzPC=>
SN12C MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTaW2oyOCEQvF2= NHjXcmY4OiCq M4TLZ2ROW09? M4DOVGlEPTB;MUCg{txO MlixNlM5PDRyM{i=
SNB-19 NIXPOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\v[moyOCEQvF2= NXzUdZFzPzJiaB?= MX3EUXNQ NXHuXmRRUUN3ME2xNEDPxE1? NVnwOWNDOjN6NESwN|g>
SNU-5 M3u4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxNEDPxE1? M2TGR|czKGh? NFjwOohFVVOR MVfJR|UxRTFyIN88US=> MWSyN|g1PDB|OB?=
SNU-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne0NVAh|ryP MUG3NkBp NFf0ZnlFVVOR NEfnV4FKSzVyPUGwJO69VQ>? MWeyN|g1PDB|OB?=
SNU-398 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK2NVAh|ryP NXfvb3pVPzJiaB?= Mlu1SG1UVw>? M4\DXWlEPTB;MUCg{txO NHfUOm8zOzh2NECzPC=>
SNU-449 NVfPT2lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL5OXEyOCEQvF2= NVXKPZA4PzJiaB?= NIPzVHJFVVOR NUPzUlQ2UUN3ME2xNEDPxE1? MlTBNlM5PDRyM{i=
SR MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzTZ2IyOCEQvF2= NYnwcYhiPzJiaB?= NIe0bHZFVVOR M13oOmlEPTB;MUCg{txO NUDO[ml6OjN6NESwN|g>
ST486 M1e2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn4XJQyOCEQvF2= NXXxT5Q3PzJiaB?= NHvwWWtFVVOR NUPTemxPUUN3ME2xNEDPxE1? M4LiXFI{QDR2MEO4
SW579 MlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrNNVAh|ryP NXHpbmF{PzJiaB?= MmrtSG1UVw>? MnnaTWM2OD1zMDFOwG0> NYK4XmF[OjN6NESwN|g>
SW684 NX3DR4Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfyNVAh|ryP NH[5TZA4OiCq NH7scnlFVVOR MlfLTWM2OD1zMDFOwG0> NYPVO4J5OjN6NESwN|g>
SW-780 NY\pdZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNEDPxE1? MYO3NkBp M1;lc2ROW09? NF3jcIxKSzVyPUGwJO69VQ>? MkDzNlM5PDRyM{i=
SW900 NHn0SnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC0RmpWOTBizszN NHq2cnU4OiCq M4WyUWROW09? NIDTS5FKSzVyPUGwJO69VQ>? MVSyN|g1PDB|OB?=
SW1088 NUj5S3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7RNVAh|ryP MUG3NkBp MUfEUXNQ MlW5TWM2OD1zMDFOwG0> NYi3TZNnOjN6NESwN|g>
SW1463 NGrGW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTFfHZUOTBizszN NX7CT4R2PzJiaB?= Mkn3SG1UVw>? NF6xNnNKSzVyPUGwJO69VQ>? MV2yN|g1PDB|OB?=
SW1990 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tzb|ExKM7:TR?= MUW3NkBp NID3T5pFVVOR NXLnTYJLUUN3ME2xNEDPxE1? M130dFI{QDR2MEO4
T47D NXvHU5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNEDPxE1? MmnwO|IhcA>? NXu5VJB[TE2VTx?= Mmn3TWM2OD1zMDFOwG0> MnvMNlM5PDRyM{i=
TE381.T NEnOVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWxNEDPxE1? M3fJRVczKGh? M1vkRWROW09? M3H6SmlEPTB;MUCg{txO M1iydFI{QDR2MEO4
TK-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnrOXZtOTBizszN MojEO|IhcA>? MmjOSG1UVw>? NYrCVHlUUUN3ME2xNEDPxE1? M376fVI{QDR2MEO4
U2OS NIHpfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixNEDPxE1? MlrIO|IhcA>? NHvnTVVFVVOR Mn;wTWM2OD1zMDFOwG0> MXiyN|g1PDB|OB?=
U251 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfaNVAh|ryP MmD3O|IhcA>? M3vGTWROW09? NUi5SWUxUUN3ME2xNEDPxE1? NIizcoszOzh2NECzPC=>
UACC-812 NGm5XHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS0NpVNOTBizszN M1PS[VczKGh? M1jifmROW09? NUTpXm1oUUN3ME2xNEDPxE1? MX:yN|g1PDB|OB?=
YAPC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGxNEDPxE1? MmK5O|IhcA>? NEjKPWZFVVOR NVr1bXRKUUN3ME2xNEDPxE1? MUKyN|g1PDB|OB?=
ZR-75-1 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv4PVEyOCEQvF2= NGLob2o4OiCq M3fEPGROW09? Moi0TWM2OD1zMDFOwG0> M{PKN|I{QDR2MEO4
A375 M1[5UWZ2dmO2aX;uJIF{e2G7 MnvpNU4zKM7:TR?= NF\PNmQ1KGh? NIP3VmNFVVOR NGPsdlJKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?= MX:yNlM5QTR5MR?=
YUSIT1 M4H6XWZ2dmO2aX;uJIF{e2G7 MnHnSG1UVw>? M3jKZ5Jm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR|UxKD5iMD61JO69VQ>? NGLPfIgzOjN6OUS3NS=>
MeWo MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PmZ2ROW09? NXzoPGlsUUN3MDC9JFk5PyCwTR?= M{T6eFI3ODF6NUK0
WiDr MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmS1SG1UVw>? NX;CSoFHUUN3MDC9JFc3KG6P NYG5bnBsOjZyMUi1NlQ>
Colo-205 MVHGeY5kfGmxbjDhd5NigQ>? MXWxJO69VQ>? M2jrclQh\A>? MWrEUXNQ NYDHemxwUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn M1PPWlI2OzhzMUWy
RBW-1 NF\ue4lHfW6ldHnvckBie3OjeR?= NH;LUJQyKM7:TR?= NEi3eoNFVVOR NVjxS4J[Vm9icnXkeYN1cW:wIH;mJG1mcyBzL{KgdIhwe3Cqb4L5cIF1cW:w MYCyOFg5PTZ7MB?=
RBO-1 M2LRbmZ2dmO2aX;uJIF{e2G7 MoO2NUDPxE1? M4r2fWROW09? NYLU[mRrUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NV7he2RTOjR6OEW2PVA>
RBO-2 NF60bYNHfW6ldHnvckBie3OjeR?= Mk\0NUDPxE1? MY\EUXNQ NF3EdlVKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? MX6yOFg5PTZ7MB?=
RBOW NWDBeYhETnWwY4Tpc44h[XO|YYm= NVrjUndzOSEQvF2= MYTEUXNQ NXjtU29DUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? NGrJNGYzPDh6NU[5NC=>
M257 NU\wR5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNFAhdk1? MY[3NkBp MmXQSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI MkfKNlM{OTd2NE[=
LCP MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvhNVAxKG6P MWe3NkBp NYf2OIZvUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>? MUKyN|MyPzR2Nh?=
WM266 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNFAhdk1? M4P2OVczKGh? M{DE[mlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>? M2r5UVI{OzF5NES2
M257 M2HTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1iweVExOCCwTR?= NGDjfW84OiCq NGDpbplFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= NYDxNHZZOjN|MUe0OFY>
LCP NE\YPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnocWFYOTByIH7N NVHCPItmPzJiaB?= MXrJcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v NGHmXXczOzNzN{S0Oi=>
WM266 NFnhNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xNFAhdk1? MWm3NkBp NHLFeG9KdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36= M2HkS|I{OzF5NES2

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03272464 Recruiting Melanoma Massachusetts General Hospital|Incyte Corporation November 30 2018 Phase 1
NCT03668431 Recruiting Metastatic Colorectal Cancer Massachusetts General Hospital|Novartis|Stand Up To Cancer October 15 2018 Phase 2
NCT02672358 Withdrawn Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis September 3 2018 Phase 2
NCT03551626 Recruiting Malignant Melanoma Novartis Pharmaceuticals|Novartis August 29 2018 Phase 3
NCT03455764 Recruiting Melanoma Dana-Farber Cancer Institute|Novartis June 22 2018 Phase 1|Phase 2
NCT03553329 Completed Unresecable Stage IIIc or IV Melanoma Poitiers University Hospital June 2 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID